The Current and Potential Clinical Relevance of Heart Failure Biomarkers.

Abstract

Heart failure is a growing epidemic, and our understanding of the intricacies of its pathophysiology continues to evolve. Over the last decade, biomarkers of heart failure have been extensively investigated, particularly for diagnosis and risk stratification. While the natriuretic peptides remain the gold standard heart failure biomarker, they are plagued by their non-specific nature; furthermore, the strategy of natriuretic peptide-guided care remains elusive. Multiple candidate markers indicative of other physiologic aspects of heart failure have been identified and studied, including soluble ST2, galectin-3, and high-sensitivity cardiac troponins. Each of these biomarkers has the potential to provide unique therapeutically relevant information. Ultimately, a multi-marker approach may be applied to improve care of patients with heart failure. Definitive clinical trials and the use of advanced statistical analytic techniques are needed to truly determine the optimal strategy of biomarker-assisted diagnosis, prognostication, and management of patients who suffer from this devastating condition.

• Authors: Parul U Gandhi, Jeffrey M Testani, Tariq Ahmad
• Journal: Current heart failure reports (Curr Heart Fail Rep) Vol. 12 Issue 5 Pg. 318-27 (Oct 2015) ISSN: 1546-9549 [Electronic] United States
• PMID: 26280466 (Publication Type: Journal Article, Review)

Chemical References

• Biomarkers
• Natriuretic Peptides

Topics

• Biomarkers (blood)
• Drug Monitoring (methods)
• Heart Failure (diagnosis, drug therapy)
• Humans
• Natriuretic Peptides (blood)
• Prognosis
• Research Design
• Treatment Outcome